NCT05214690已完成1 期
A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of DW1809-T2 and DW1809-1 in Healthy Adult Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- Peak Plasma Concentration (Cmax)
研究概览
简要总结
Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy Volunteers who are ≥19 years old
- •Body weight ≥50.0 kg and BMI between 18.0 and 30.0 kg/m2 and
排除标准
- •Clinically significant Medical History
- •In the case of women, pregnant(Urine-HCG positive) or lactating women
研究组 & 干预措施
Sequence B
Experimental
cross-over
干预措施: DW1809-T2 (Drug)
Sequence B
Experimental
cross-over
干预措施: DW1809-1 (Drug)
Sequence A
Experimental
cross-over
干预措施: DW1809-T2 (Drug)
Sequence A
Experimental
cross-over
干预措施: DW1809-1 (Drug)
结局指标
主要结局
Peak Plasma Concentration (Cmax)
时间窗: up to 8 hour
Pharmacokinetics of Pelubiprofen
Area under the plasma concentration versus time curve (AUC)
时间窗: up to 8 hour
Pharmacokinetics of Pelubiprofen
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809OsteoarthritisBack PainAcute Upper Respiratory Tract InfectionRheumatoid ArthritisNCT05214677Daewon Pharmaceutical Co., Ltd.38
已完成
1 期
CKD-828 (80/5mg) Pharmacokinetic StudyHypertensionNCT02358824Chong Kun Dang Pharmaceutical48
招募中
1 期
A Comparing Study Between SJ04 and Ovidrel® in Healthy SubjectsAssisted Reproductive TechnologyFemale InfertilityNCT06599528Suzhou Centergene Pharmaceuticals Co.,Ltd.48
已完成
1 期
Pharmacokinetics of HCP1401 and Co-administration of HCP0605, HGP1405 in Healthy Male VolunteersHealthyNCT04252872Hanmi Pharmaceutical Company Limited64
已完成
1 期
Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy VolunteersChemotherapy-Induced NeutropeniaNCT02700360Enzychem Lifesciences Corporation36